ViGenCell Inc. (KOSDAQ:308080)

South Korea · Delayed Price · Currency is KRW

6,260.00

+80.00 (1.29%)

At close: Sep 3, 2026

Market Cap	134.89B +73.8%
Revenue (ttm)	278.95M
Net Income	-12.56B
EPS	-650.72
Shares Out	20.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	190,176
Open	6,200.00
Previous Close	6,180.00
Day's Range	6,100.00 - 6,500.00
52-Week Range	3,070.00 - 17,360.00
Beta	1.86
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ViGenCell

ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, Sou... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2013

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 308080

Full Company Profile

Financial Performance

Financial Statements